Free Newsletter
Register for our Free Newsletters
Analysis, Inspection and Laboratory
Assisted/Independent Living
Clinical and Nursing Equipment
Design and Manufacture of Medical Equipment
Diagnostics Equipment, Monitoring and Test
Education, Training and Professional Services
Health Education and Patient Management
Health Estates Management
Healthcare Support and Information Services
Hygiene and Infection Control
IT and Communications in Healthcare
Medical Device Technology
Research and Development
Safety and Security
View All
Other Carouselweb publications
Carousel Web
Defense File
New Materials
Pro Health Zone
Pro Health Zone
Pro Security Zone
Web Lec
Pro Engineering Zone

Thermo Fisher Scientific agrees to partner Megaware for software developments

Thermo Fisher Scientific Informatics : 12 June, 2007  (New Product)
Thermo Fisher Scientific has formed a new strategic partnership with Megaware to market a new end-to-end software solution that provides bioequivalence functionality on a single platform to help speed up and manage clinical trials.
The solution and services will be delivered to pharmaceutical, biotech and Contract Research Organizations (CROs).

Rapid market growth in generic drug production is driving the requirement for fast efficient bioequivalence studies to meet FDA ANDA guidelines (Abbreviated New Drug Applications).

A unified software solution will aggregate disparate software systems for organizations that demand tools to speed service and management of this critical and regulated IPO.

'The market for bioequivalence studies in India and the Far East is growing rapidly, and the Thermo Scientific Watson LIMS is seen as the de facto standard for bioanalysis/equivalence', said Dave Champagne, vice president and general manager of informatics for Thermo Fisher.

'Thermo Fisher's unparalleled strength in this field complements Megaware's in-depth experience with the CRO industry in the market'.

'Our collaboration with Megaware will lead to the first total solution for this market, eliminating time and administrative burden from the bioequivalence challenge'.

The two companies will work together closely to target the market for bioanalysis/equivalence studies, initially in India and thereafter across the Far East and other markets.

The market in India for clinical trials is growing rapidly, because the average cost of trials is significantly lower than in the United States and Europe.

The consultancy firm McKinsey estimates that US and European pharmaceutical companies will spend $1.5 billion per year on clinical trials in India by 2010.

Thermo Fisher and Megaware will jointly sell, market and support the new solution in the field.

Thermo Fisher will bring its bioanalytical expertise to the partnership and Megaware, with headquarters in Westborough, MA, USA, and Mumbai, India, will deliver the end-to-end technological focus combined with on-the-ground market knowledge.

The new solution will offer higher throughput, greater levels of compliance and standardisation of bioequivalence processes.

'We have an established customer base in contract research and pharmaceutical companies in India, who are encouraged by the development of robust enterprise automation solution to enable them to gain FDA approval quicker', adds Ajit Nagral, president of Megaware.

'We believe that Thermo Fisher, and Megaware, together deliver the best-in-breed solution for this market.'

Bookmark and Share
Home I Editor's Blog I News by Zone I News by Date I News by Category I Special Reports I Directory I Events I Advertise I Submit Your News I About Us I Guides
   © 2012
Netgains Logo